CSF2 and neoplasm: In murine models, Li et al. demonstrated that VEGF blockade (by expression of a soluble chimeric VEGF receptor – sVEGFR1/R2) improved the efficacy of a GM-CSF-secreting tumor-cell immunotherapy.